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Background: We have previously reported a favourable response rate in patients with advanced esophageal
cancer after treatment with a biweekly regimen of paclitaxel and cisplatin. In this study we investigate the feasi-
bility and efficacy of this regimen in a neo-adjuvant setting.
Patients and methods: Patients with resectable squamous cell carcinoma of the esophagus received paclit-
axel 180 mg/m2 and cisplatin 60 mg/m2 every 2 weeks. Patients received three courses and responding patients
received three additional courses; thereafter, patients were referred for surgery. Patient characteristics of 50 eligible
patients were as follows: male, 60%; median age, 62 years (range 45–78); median World Health Organization
performance status of 1 (range 0–2).
Results: Ninety-four per cent of patients received at least three courses of chemotherapy. Haematological
toxicity consisted of National Cancer Institute–Common Toxicity Criteria grade 3 or 4 neutropenia in 71% of
patients, with neutropenic fever occurring in only two patients (4%). The overall response rate was 59%. Patho-
logical examination showed tumour-free margins in 38 patients. In seven patients no residual tumour was found.
The median overall survival was 20 months and the 1- and 3-year survival rates were 68% and 30%, respect-
ively.
Conclusions: This dose-dense schedule of paclitaxel and cisplatin administered biweekly is well tolerated and
the observed overall and complete response rates are promising.
Key words: biweekly, cisplatin, esophageal cancer, neo-adjuvant, paclitaxel
Introduction
Patients who present with esophageal cancer have a poor prog-
nosis. Most patients thought to have resectable disease already
have extension into the adventia or through the esophageal wall
and/or regional lymph node involvement at the time of diagnosis.
The 5-year survival rate of these patients after surgical resection is
only 20% [1, 2]. The pattern of failure includes both local recur-
rence as well as distant metastases.
One way to improve the prognosis of patients with resectable
esophageal cancer might be the incorporation of neo-adjuvant
chemotherapy. The goals of neo-adjuvant chemotherapy are a
reduction of recurrence from occult lymphatic and/or distant
metastases with improvement of survival and possible tumour
shrinkage with an increased resectability rate.
Most studies of neo-adjuvant chemotherapy have demonstrated
that patients achieving an objective response have a significantly
better survival compared with non-responding patients [3]. Never-
theless, overall survival remains poor and therefore development
of chemotherapy regimens with high response rates and which can
be administered to patients with a moderate performance score is
a high priority. Paclitaxel has been found to be an active agent in
esophageal cancer, either alone or in combination with cisplatin.
Ilson et al. [4, 5] investigated conventional 3-week schedules of
cisplatin and paclitaxel with or without 5-fluorouracil (5-FU) in
patients with advanced oesophageal cancer. The reported response
rates were 48% and 44%, respectively. However, in both studies
the observed toxicity was substantial, including hospitalisation
due to gastrointestinal and haematological toxicity in half of the
patients.
In our centre, we have obtained experience with the use of dose-
dense chemotherapy regimens with cisplatin and paclitaxel. In a
phase I study, we treated patients with advanced esophageal
cancer with a biweekly administration of cisplatin 60 mg/m2 and
escalating doses of paclitaxel (3-h infusion) [6]. The recom-
mended dose for paclitaxel was 180 mg/m2, because at higher
doses sensory neuropathy became the dose-limiting toxicity. In
a subsequent phase II study we confirmed the feasibility of this
regimen, and the observed response rates in these two studies were
52% and 43%, respectively [6, 7]. Both the high response rates
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and the excellent clinical tolerability of this biweekly regimen of
cisplatin and paclitaxel urged us to test this regimen in a neo-
adjuvant phase II setting in patients with resectable squamous cell
carcinoma of the esophagus.
Patients and methods
Patients
Patients with histologically confirmed squamous cell carcinoma of the
oesophagus and with no signs of irresectability and no evidence of metastatic
disease were eligible for the study. The tumour had to be limited to the
oesophagus and regional lymph nodes without involvement of the tracheo-
bronchial tree or other structures. Further eligibility requirements were as
follows: age ≥18 years; no contraindications for extensive surgery; World
Health Organization (WHO) performance status of ≤2; written and voluntary
informed consent; and adequate haematological, renal and hepatic functions
(granulocytes ≥1.5 × 109/l, platelets ≥100 × 109/l, total bilirubin <1.5 × upper
normal limit and creatinine <120 µmol/l). Exclusion criteria were as follows:
previous treatment with chemotherapy or radiotherapy; pre-existing neuro-
toxicity greater than National Cancer Institute–Common Toxicity Criteria
(NCI-CTC) grade 1 and inadequate calorie and/or fluid intake. The study was
approved by the local ethics committee.
Initial evaluation
Initial evaluation included a complete medical history, physical examination,
complete blood cell count and serum biochemistry endoscopy with biopsies,
endoscopic ultrasonography, ultrasonography of the supraclavicular region
and a computed tomography (CT) scan of the chest and abdomen.
Chemotherapy
Paclitaxel 180 mg/m2 and cisplatin 60 mg/m2 were administered by i.v. infu-
sion every 2 weeks. After prehydration with at least 1 l of normal saline, the
calculated dose of paclitaxel, diluted in 500 ml of normal saline, was infused
over 3 h. Hereafter, the calculated dose of cisplatin was administered over 3 h
followed by posthydration with 3 l of normal saline over 24 h. Thirty minutes
prior to the paclitaxel infusion, the patients received dexamethasone 10 mg,
clemastine 2 mg and ranitidine 50 mg, all given intravenously. Ondansetron
8 mg i.v. was routinely given. Patients were retreated when the granulocytes
were ≥0.75 × 109/l and platelets ≥75 × 109/l. When these criteria were not met,
treatment was postponed for 1 week.
Tumour response was assessed after the third course of chemotherapy and
included a CT scan of chest and abdomen and an endoscopic examination.
Non-responding patients were referred for surgery. Patients showing disease
regression received three additional courses of chemotherapy. These patients
were again evaluated after the sixth course and then referred for surgery.
Toxicity was graded and reported using NCI-CTC criteria (version 2) and
response was evaluated using standard WHO criteria [8].
Surgery
For carcinomas proximal to the carina, the esophagus was resected by a right
dorso-lateral thoracotomy. For more distal carcinomas the transhiatal approach
was preferred. Accessible intra-abdominal, peri-esophageal and subcarinal
lymph nodes were sampled. Post-operative radiotherapy or chemotherapy was
not given.
The tumour stage after resection was classified according to the TNM clas-
sification of the International Union Against Cancer (UICC, fifth edition,
1997). To describe the absence or presence of residual tumour after resection
of the primary tumour, the following residual (R) categories were used as
appendices: R0 if all the surgical margins were free of tumour; R1 if there was
microscopically residual tumour in any of the surgical margins; and R2 if
macroscopically residual tumour was detected.
Any type of complication occurring after surgery was considered post-
operative morbidity. Treatment-related mortality was defined as any death that
occurred before a patient was discharged, or even after discharge when there
was any possible correlation with the treatment itself.
Statistical considerations
Patient enrolment followed a four-step sequential design. If no response was
seen in the first eight patients further accrual had to be halted. Otherwise, an
additional 12 patients could be entered. In the third step, 10 more patients were
entered if at least four responses were observed in the 20 patients that were
treated. Finally, when 30 patients were treated the trial was to be continued
with an additional 20 patients if the observed number of responses was at least
50%. Under this design there is only an 18% chance of continuing the trial
while the true response percentage is <40%.
Survival time was measured from date of inclusion to death or was censored
at the time that the patient was last known to be alive. Median survival times
and survival curves were estimated using the method of Kaplan and Meier.
Results
From October 1997 to February 2000, 51 patients entered the
study. One patient was ineligible because he had a carcinoma of
the gastric cardia. Patient characteristics are listed in Table 1.
Table 1. Patient characteristics (n = 50)
aEndoscopic ultrasonography.
WHO, World Health Organization.
Characteristic No. of 
patients
%
Sex
Male 30 60
Female 20 40
Age (years)
Median 62
Range 45–78
WHO performance status
0 20 40
1 26 52
2 4 8
Weight loss (%)
0–5 21 42
5–10 10 20
>10 19 38
TNM classificationa
T2N0 1 2
T3N0 10 20
T2N1 6 12
T3N1 21 42
No pass 12 24
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Chemotherapy
Of 50 eligible patients, 47 patients (94%) received at least three
courses of chemotherapy. One patient refused further treatment
after one course of chemotherapy. This patient was considered not
evaluable for toxicity and response. In two other patients, treat-
ment was stopped after two courses due to grade 2 sensory
neuropathy. Both patients were evaluated and referred for surgery.
Thirteen patients with stable disease after three courses were
referred for surgery according to the protocol. Treatment was con-
tinued in the remaining 34 patients who had at least objective
tumour regression at evaluation, although not always qualifying
for partial response. Seven of these patients did not receive the
planned next three courses due to sensory neuropathy (four
patients) and deterioration of general condition mainly due to
fatigue and myalgia (three patients).
Sixty-three cycles (26%) were delayed for 1 week in 26
patients. The reason for the delay of treatment was in almost all
cases a granulocyte count <0.75 × 109/l at the day of retreatment.
The planned and achieved dose intensities for cisplatin were
30 mg/m2/week and 26.6 mg/m2/week, respectively, and for
paclitaxel, 90 mg/m2/week and 79.8 mg/m2/week, respectively.
The predominant toxicities are listed in Table 2. Neutropenia
grade 3 or 4 was observed in 35 patients (71%), with neutropenic
fever occurring in only two patients (4%). Both patients recovered
after treatment with broad-spectrum antibiotics. Non-haemato-
logical toxicities were usually mild. Sensory neuropathy, the most
important non-haematological toxicity, was observed in 25
patients (51%) but never exceeded grade 2. The overall response
rate in 49 evaluable patients was 59%; seven patients (14%) had a
complete response and 22 patients (45%) had a partial response.
Stable disease was observed in 20 patients (41%). No patient had
disease progression during treatment.
Surgery
Three patients (6%) were not referred for surgery. These patients
had large tumours located above the carina and enlarged mediastinal
lymph nodes that remained unchanged during chemotherapy, and
were considered not fit enough for thoracotomy due to co-
morbidity and a deteriorating general condition. All three patients
received radiation therapy up to a total dose of 50 Gy.
Forty-seven patients (94%) were referred for surgery. Surgery
was performed between 4 and 6 weeks after completion of chemo-
therapy in all patients. In 45 patients (90%), a resection was
carried out. In two patients, who had a locally irresectable tumour
or intra-abdominal lymph node metastasis, a resection was not
carried out. In 28 patients a transhiatal approach without thorac-
otomy was performed, while 17 patients underwent a transthoracic
esophagectomy.
Of the 45 patients that underwent oesophageal resection, 38
patients (84%) had an R0 resection and seven patients (16%) had
an R1 resection. Pathological examination of the resected specimens
showed no residual tumour in seven patients. Five of these seven
patients had been clinically evaluated as complete responders. A
comparison of the pre- and post-treatment staging of all 50
patients is listed in Table 3.
Post-operative complications occurred in 26 of 45 patients
(58%) (Table 4). Two patients died in the post-operative period
(4%). One patient died of cardiovascular complications directly
after surgery and one patient died of respiratory complications
3 months after surgery.
Table 2. Worst NCI-CTC grade toxicities (n = 49)
NCI-CTC, National Cancer Institute–Common Toxicity Criteria.
CTC grade (%)
0 1 2 3 4
Granulocytopenia 4 10 14 18 53
Thrombocytopenia 96 4
Nausea 45 37 14 4
Vomiting 57 31 8 4
Diarrhoea 90 8 2
Mucositis 96 4
Neurotoxicity 49 37 14
Myalgia 47 35 18
Fatigue 51 37 12
Table 3. Pre- and post-treatment stagea
aStage grouping according to the International Union Against Cancer, 
5th edition.
bStaged by endoscopic ultrasonography.
cStaged by pathological examination.
Stage Pre-chemotherapy 
n (%)b
Post-chemotherapy 
n (%)c
T0N0 0 7 (14)
I 0 4 (8)
IIA 11 (22) 19 (38)
IIB 6 (12) 6 (12)
III 21 (42) 6 (12)
IV 0 3 (6)
No pass/unknown 12 (24) 5 (10)
Table 4. Postoperative course and morbidity
Characteristic No. of patients (%)
Operative mortality 0 (0)
30-day hospital mortality 1 (2)
Median days of hospital stay (range) 15 (8–96)
Postoperative course
Uneventful 19 (42)
Complications 26 (58)
Respiratory 14 (32)
Sepsis 2 (4)
Anastomotic leakage 7 (13)
Bleeding 1 (2)
Vocal cord paralysis 12 (27)
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Survival and pattern of failure
After a median follow-up period of 41 months (18–54 months), 18
of 50 patients were alive, 17 of them showed no recurrence of dis-
ease. The median actuarial survival in all patients was 20 months
(3–>50 months), with a 1- and 3-year survival rate of 68% and
32%, respectively. Responders had a significantly better median
survival than non-responding patients (32 versus 11 months;
P = 0.009) (Figure 1). The pattern of disease recurrence in 27
patients was locoregional recurrence in six patients, metastatic
disease only in 17 patients and both locoregional and distant
disease in four patients.
Discussion
Previous phase II studies with neo-adjuvant chemotherapy have
shown encouraging results in patients with squamous cell car-
cinoma. Response rates of 15–60% with a complete pathological
response rate of 4–7% after cisplatin-based combination chemo-
therapy have been reported [9]. Compared with historical controls
the outcome seemed improved after treatment with pre-operative
chemotherapy [10].
In two large randomised trials neo-adjuvant chemotherapy
followed by surgery was compared with surgery alone [11, 12].
Noteworthy are the conflicting results of the two largest trials. The
Medical Research Council (MRC) found a significantly improved
survival following neo-adjuvant chemotherapy [11]. In their
study, 802 patients with resectable esophageal cancer were ran-
domised to receive pre-operative chemotherapy with two courses
of cisplatin and 5-FU followed by surgery or surgery alone. The
median survival was 17 months for patients treated with pre-
operative chemotherapy versus 13 months after surgery alone
[P = 0.004; hazard ratio 0.79; 95% confidence interval (CI) 0.67–
0.93]. In the Intergroup trial 440 patients were randomised to pre-
operative treatment with three courses of cisplatin and 5-FU
followed by surgery, or surgery alone [12]. Median survival was
comparable in the two groups, 15 months after pre-operative
chemotherapy and 16 months after surgery alone (P = 0.53;
hazard ratio 1.07; 95% CI 0.87–1.32).
The conflicting results of the randomised studies are difficult to
explain, particularly because comparable chemotherapy regimens
were used. A possible explanation is the type of surgical resection
carried out. In the Intergroup study a transthoracic esophagectomy
was preferred, while in the MRC study both the transthoracic
esophagectomy and the transhiatal esophagectomy were con-
sidered appropriate; however, the number of transhiatal resections
has not been reported. A transthoracic approach makes a more
extended lymph node resection possible and it could be that the
benefit of pre-operative chemotherapy in the positive studies was
only the result of improved local control in patients treated with
less extensive surgery. However, in a recently reported trial com-
paring transhiatal esophagectomy with transthoracic esophag-
ectomy with extended lymphadenectomy there was only a trend
toward improved long-term survival at 5 years with the extended
transthoracic approach [13]. A transhiatal esophagectomy was
associated with lower morbidity.
In the current study, we treated 50 patients with a resectable
squamous cell carcinoma of the esophagus with a biweekly regi-
men of paclitaxel and cisplatin. This dose-dense treatment was
well tolerated and achieved an overall clinical response rate of
59%. Despite the fact that 71% of patients developed grade 3 or 4
neutropenia, we observed only two episodes of neutropenic fever.
The majority of patients included in our study had T3 tumours
with positive regional lymph node involvement. Forty-five patients
(90%) underwent an esophageal resection and the mortality rate
was not apparently increased. Pathological examination showed
no residual tumour in seven patients (14%) and an R0 resection in
38 patients (76% of all patients and 83% of patients that under-
went a resection). The median survival was 20 months and the
1- and 3-year survivals were 68% and 32%, respectively.
Both the overall and complete response rates observed in this
study, 59% and 14%, respectively, seem to compare favourably
with the response rates observed in other studies with neo-adjuvant
chemotherapy. In addition, this dose-dense regimen of cisplatin
and paclitaxel was well tolerated and 94% of patients were able to
complete the first three courses of chemotherapy. In the Inter-
group study, for example, only 71% of patients completed the
three pre-operative chemotherapy courses [12].
The design of our study and the chemotherapy regimen differed
in several aspects from other studies. This is the first study investi-
gating a neo-adjuvant regimen of dose-dense cisplatin and
paclitaxel. Theoretical advantages of a dose-dense schedule could
be that more cancer cells are being killed, because there is less
time for the tumour to regrow between drug administrations, and
that a more continuous exposure to cytotoxic agents may perma-
nently impair growth-promoting intracellular signalling and DNA
repair [14]. Furthermore, the study design differed from that of the
other trials because we administered three additional courses to
responding patients. Although the optimal number of pre-
operative chemotherapy courses has not been established, the
administration of additional courses to responding patients could
have resulted in an increased complete response rate and possible
improved survival.
Figure 1. Kaplan–Meier survival curve for responding (n = 29; continuous 
line) and non-responding (n = 20; dotted line) patients, P = 0.008 (log rank).
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In conclusion, this dose-dense schedule of cisplatin and paclit-
axel administered biweekly is well tolerated by patients with
resectable squamous cell carcinoma of the esophagus. The overall
and complete response rates obtained with this combination are
promising. Further evaluation comparing this treatment with other
treatment strategies in a randomised trial is warranted.
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